CNS RESP Stock OTC Bulletin Board
Equities
CNSOD
US12619C2008
Biotechnology & Medical Research
Sales 2021 | 20.61M 28.17M | Sales 2022 | 18.39M 25.14M | Capitalization | 12.9M 17.63M |
---|---|---|---|---|---|
Net income 2021 | -15M -20.5M | Net income 2022 | -10M -13.67M | EV / Sales 2021 | 4.97 x |
Net Debt 2021 | 20.13M 27.52M | Net Debt 2022 | 28.8M 39.37M | EV / Sales 2022 | 2.27 x |
P/E ratio 2021 |
-5.16
x | P/E ratio 2022 |
-1.21
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.23% |
Managers | Title | Age | Since |
---|---|---|---|
George Sekulich
PSD | President | 59 | 19-04-30 |
Willis Lee
CHM | Chairman | 64 | 19-07-16 |
Yasushi Nagasaki
DFI | Director of Finance/CFO | 57 | 11-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Peu Zen
BRD | Director/Board Member | 71 | 19-07-16 |
Willis Lee
CHM | Chairman | 64 | 19-07-16 |
Ian Zwicker
BRD | Director/Board Member | 77 | 19-07-16 |
1st Jan change | Capi. | |
---|---|---|
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |